Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Research & Development (2016 - 2023)

Historic Research & Development for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to $1.2 million.

  • RedHill Biopharma's Research & Development fell 1528.53% to $1.2 million in Q2 2023 from the same period last year, while for Jun 2023 it was $5.1 million, marking a year-over-year decrease of 6870.53%. This contributed to the annual value of $1.6 million for FY2024, which is 5498.87% down from last year.
  • RedHill Biopharma's Research & Development amounted to $1.2 million in Q2 2023, which was down 1528.53% from $1.1 million recorded in Q1 2023.
  • In the past 5 years, RedHill Biopharma's Research & Development registered a high of $10.3 million during Q2 2021, and its lowest value of $1.1 million during Q1 2023.
  • Its 5-year average for Research & Development is $4.1 million, with a median of $3.1 million in 2020.
  • In the last 5 years, RedHill Biopharma's Research & Development skyrocketed by 22134.41% in 2021 and then crashed by 8574.75% in 2022.
  • Over the past 5 years, RedHill Biopharma's Research & Development (Quarter) stood at $2.3 million in 2019, then skyrocketed by 171.92% to $6.2 million in 2020, then decreased by 5.19% to $5.9 million in 2021, then crashed by 80.69% to $1.1 million in 2022, then increased by 10.06% to $1.2 million in 2023.
  • Its last three reported values are $1.2 million in Q2 2023, $1.1 million for Q1 2023, and $1.1 million during Q4 2022.